Protein patterns in various malignant human brain tumors by two-dimensional gel electrophoresis.

Two-dimensional gel electrophoresis with silver staining was used to study protein patterns in various malignant human brain tumors obtained at surgery. These samples included 20 high-grade astrocytomas (anaplastic astrocytomas and glioblastomas), one low-grade astrocytoma, six juvenile astrocytomas, four ependymomas, and five medulloblastomas. Histological correlates of the sampled tissue were carefully established prior to micropunch sampling. The molecular weight range of these gels was 14,000 to 100,000, and the isoelectric points ranged from 4.7 to 7.0. Proteins that have been identified include albumin, actin, tubulin, glial fibrillary acidic protein, vimentin, glutamic oxaloacetic transaminase, neuron-specific enolase, and the beta-subunit of the guanine nucleotide regulatory proteins. Each type of tumor was found to have a characteristic protein profile that set it apart from the other tumors studied. By providing a convenient tool for the display of a wide spectrum of tumor markers in a single study, two-dimensional gel electrophoresis protein profiles may be useful as diagnostic and prognostic adjuncts. Furthermore, several protein spots that were not noted in normal human cortex were identified in the various tumor gels. Antibodies can be raised against some of these tumor-associated proteins, and their further characterization could provide valuable insights into the biology of these tumors.

MRI monitoring of vigabatrin-induced intramyelinic edema in dogs.

Chronic administration of vigabatrin (gamma-vinyl GABA) in dogs produces reversible microvacuolation (intramyelinic edema) in discrete brain regions. Histologic changes are most notable in the columns of the fornix and regions of the hypothalamus, thalamus, optic tract, and hippocampus. In an attempt to image these changes in vivo, we performed high-field MRI on seven treated and four control dogs at baseline and after 15 weeks of dosing with vigabatrin (300 mg/kg/d). All dogs underwent parallel electrophysiologic assessment to determine the effects of vigabatrin on afferent conduction. At 15 weeks, all treated dogs showed increased T2- and decreased T1-weighted signals, with changes from baseline most prominent in the columns of the fornix and to a lesser degree in the surrounding hypothalamus and thalamus. MRIs performed on control dogs were unremarkable. We then perfused a random selection of four treated and two control dogs and imaged their brains ex vivo prior to sectioning. Ex vivo imaging confirmed the in vivo findings and strongly correlated with both electrophysiologic and subsequent histopathologic findings. Imaging was repeated in the surviving dogs 5 and 12 weeks after discontinuation of dosing. Signal abnormalities in the treated dogs progressively diminished during recovery, paralleling the electrophysiologic and histopathologic results. These findings demonstrate that MRI can detect signal changes anatomically congruent with vigabatrin-induced intramyelinic edema and suggest that MRI may provide a useful noninvasive tool for monitoring patients during clinical trials.

Effect of chronic treatment with clorgyline on the relative concentration of specific proteins in the hippocampus and parietal cortex of the rat.

The effect of the chronic administration of clorgyline, a type A inhibitor of monoamine oxidase, on the relative concentration of proteins from the brain of the rat was examined by analysis of two-dimensional electrophoretic gels. The results from this study showed that the administration of clorgyline for 3 weeks produced a significant elevation in the relative concentration of two proteins in the parietal cortex (mol. wt 23,000 and 30,000) and one protein in the hippocampus (mol. wt 25,000). In contrast, the relative concentration of three proteins (mol. wt 31,000, 42,000 and 45,000) was significantly reduced in the parietal cortex by chronic treatment with clorgyline. No protein in the hippocampus was found to be significantly reduced by treatment with clorgyline. Since a previous study has indicated that the relative concentration of three different proteins were significantly altered by the repeated administration of desipramine, the results from the present experiment indicate that different changes in proteins are produced by repeated treatment with the type A monoamine oxidase inhibitor, clorgyline, as compared to those produced by the tricyclic antidepressant, desipramine. These results support previous suggestions that different classes of antidepressant compounds may exert their effects through different mechanisms of action.

Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.

We report the synthesis and evaluation of novel alpha1a adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent alpha1a antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a Ki of 2.8 nM, in agreement with the cloned human receptor binding data (Ki = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a Ki of 3.6 nM and confirmed it to be a potent antagonist (Kb = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBP), with a DBP Kb/IUP Kb ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that alpha1a adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective alpha1 antagonists such as prazosin and terazosin, with fewer side effects.

Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia.

Zaleplon (N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethyl acetamide) is a non-benzodiazepine recently introduced for clinical use. This agent is indicated for the short-term treatment of insomnia. Preclinical studies have shown that the benzodiazepines triazolam and Ro17-1812 can substitute for zaleplon in animals trained to distinguish zaleplon from saline. The benzodiazepine antagonist flumazenil can antagonise the discriminative stimulus effect of zaleplon. These findings suggest that zaleplon is recognised by animals as a benzodiazepine agent. Zaleplon is active after ip. and oral administration in a variety of motor performance tests, including locomotor activity, rotarod and the loaded grid. Zaleplon has been shown to be active in a number of different anticonvulsant models, including the pentylenetetrazole, isoniazid and electroshock models. The compound is also reported to be active against convulsions induced by bicuculline, picrotoxin and strychnine. Studies in anxiolytic models suggest that zaleplon may have weak anxiolytic activity. From preclinical studies, it appears zaleplon possesses a reduced risk of tolerance compared to triazolam, is less likely to potentiate the effects of ethanol and is unlikely to produce amnestic effects. In man, zaleplon is rapidly absorbed and undergoes extensive presystemic metabolism. The compound has a plasma half-life of approximately one hour and is metabolised primarily via the aldehyde oxidase system to form 5-oxo-zaleplon. This metabolite, along with other minor metabolites formed in vivo, do not appear to contribute to the activity of zaleplon. Metabolites of zaleplon are excreted primarily via the urine. Phase I studies suggest that single daytime doses of zaleplon up to 15 mg are well-tolerated. Short-term impairment of performance occurs when zaleplon is administered during the day at doses epsilon 20 mg. However, given the short half-life of the compound, significant impairment of daytime performance is unlikely if zaleplon is administered at bedtime or shortly after retiring for the evening. Results from Phase II/III studies suggest that zaleplon (5 - 20 mg) produces a dose-dependent reduction in sleep latency in patients suffering from primary insomnia. The clinical efficacy of zaleplon persists for at least four weeks at doses of 10 mg and 20 mg. Studies in patients with a history of drug abuse suggest that the abuse potential of zaleplon (at doses above the therapeutic dose range) is similar to that seen with the benzodiazepine triazolam.

Immunological evidence for existence of two subforms of soluble glutamic oxaloacetic transminase (sGOT) in human and rat brain.

Using a sensitive and specific antiserum, the existence of two subforms of soluble glutamic oxaloacetic transaminase in both rat and human brain has been demonstrated. In the rat, the two proteins each have a molecular mass of 47,000 daltons. The more abundant basic protein has an isoelectric point of 5.9 while the sparsely staining more acidic protein has an isoelectric point of 5.8. In the human the two proteins visualized each have a molecular mass of 43,000 daltons. The more abundant basic protein has an isoelectric point of 5.7 while the sparsely staining more acidic protein has an isoelectric point of 5.6. In both rat and human, it seems reasonable to conclude that the abundant basic protein that reacts with the antiserum is the ? subform of the enzyme, while the sparsely staining more acidic protein is the ? subform of the enzyme. These results are of interest for a number of reasons. First, they establish the existence of at least two subforms of soluble glutamic oxaloacetic transaminase in both rat and human brain. Secondly, they show that this enzyme is a major protein visible on two-dimension gels of rat and human brain and that this enzyme is widely distributed throughout the central nervous system. Finally, they positively identify two more proteins visible on two-dimension gels generated using rat or human brain tissue.

Distribution of proteins in different subcellular fractions of rat brain studied by two-dimensional gel electrophoresis.

The subcellular distribution of proteins normally visible on two-dimension gels of rat brain tissue punches and crude brain homogenate was investigated using two-dimensional gel electrophoresis and computerized scanning densitometry. Seven enriched subcellular fractions (cytosol, mitochondria, microsomes, nucleus, crude synaptic vesicles, myelin and synaptic membrane) were generated from a crude extract of rat brain. Fifty microgram samples of the crude homogenate and each fraction were then taken and the proteins within these samples separated by two-dimensional gel electrophoresis. Proteins were stained with silver and the gels then analyzed by computerized scanning densitometry. Of 136 proteins visible on two-dimension gels of the crude homogenate that were quantitatively examined, a total of 73 (54%) were identified as being primarily located in a single subcellular fraction. The majority of these 73 proteins were found to be located primarily in either the cytosolic or mitochondrial fractions, while fewer proteins were identified as being primarily located in the microsomal, nuclear or crude synaptic vesicular subfractions. In contrast, the myelin and synaptic membrane fractions were found to be the primary location for only a single protein each that is clearly visible in the crude homogenate. In addition, gels of four of the subfractions (mitochondria, cytosol, nucleus and myelin) contained proteins that are not normally visible on gels generated using a crude extract. The subcellular location of a number of proteins found previously to be altered by specific experimental manipulations was also determined, providing further information on these proteins in brain. These results should prove useful in future experiments designed towards isolating and characterizing specific proteins of neurochemical interest.

Studies on catechol-O-methyltransferase in rat brain using two-dimensional gel electrophoresis.

The presence of catechol-O-methyltransferase (COMT) in the rat brain was studied using a combination of two-dimensional gel electrophoresis (2-DE), protein blotting and a specific antiserum. Two major immunoreactive proteins were identified-one with mol. wt 23 kdalton and an isoelectric point of 5.2, the other of mol. wt 25 kdalton and an isoelectric point of 5.1. In addition, multiple lower molecular weight immunoreactive proteins, possibly corresponding to breakdown products of the enzyme, were also detected. The 23 kdalton form of COMT, which is probably the soluble form of the enzyme, is a major protein visible on silver-stained 2-D gels of rat brain. In contrast, the other proteins recognized by the antiserum were not detected by the silver stain. These results demonstrate, using 2-DE, that at least two distinct forms of catechol-O-methyltransferase are present in rat brain. In addition, since one of these proteins is stained by silver, these results also serve to identify another protein visible on 2-D electrophoretograms of rat brain.

Localization of Ca(2+)-binding proteins of rat cortex on two-dimensional gels-I. Identification of calmodulin and the b subunit of calcineurin.

At least three Ca(2+)-binding proteins were detected in rat cortex by (45)Ca(2+) autoradiography of two-dimensional electrophoretograms. The identities of two of these Ca(2+)-binding proteins were determined to be calmodulin and the B subunit of calcineurin. The identification was based upon the following criteria: (1) co-localization on polyacrylamide gels with the appropriate purified proteins, (2) staining of nitrocellulose blots with specific antisera for calmodulin and calcineurin and (3) ability to bind Ca(2+). This information is useful in that it identifies two major brain proteins visible on silver-stained two-dimensional polyacrylamide gels. In addition, this data reveals the location of an unidentified Ca(2+)-binding protein of molecular weight ? 18,000 Da and pI 5.4 on these gels.

Localization of Ca(2+)-binding proteins of rat cortex on two-dimensional gels-II. analysis of Ca(2+) binding proteins in ammonium sulfate fractions of rat brain.

A total of seven high-affinity calcium-binding proteins have been detected in rat brain. This was accomplished using a combination of ammonium sulfate fractionation, two-dimensional gel electrophoresis, western blotting and (45)Ca(2+)-autoradiography. Of these seven proteins, three are detectable in a crude tissue punch of rat cortex while four are seen only after protein enrichment with ammonium sulfate. Four of the seven proteins detected in this study have been identified: calmodulin, the B subunit of calcineurin, the intestinal vitamin D-dependent calcium-binding protein and parvalbumin. The identities of the other three proteins visualized by (45)Ca(2+)-autoradiography in this study are unknown.

Continuous light paradoxically reduces catecholamine-induced melatonin production.

Exposure of rats to continuous light for 14 days reduced the stimulation of melatonin content in the pineal gland produced by either isoproterenol administration or exposure to darkness. Since continuous light has been reported to enhance many intermediate biochemical events leading to the synthesis of melatonin, these results demonstrate the importance of examining the endproduct of an organ when evaluating the physiological significance of biochemical changes in model biological systems.

Effects of bilateral lesion of the locus coeruleus and of neonatal administration of 6-hydroxydopamine on the concentration of individual proteins in rat brain.

The role that norepinephrine plays in regulating the concentration of different proteins in the parietal cortex, hippocampus and cerebellum was assessed by investigating the effects of either a bilateral lesion of the locus coeruleus or neonatal administration of 6-hydroxydopamine. Two weeks after lesioning the locus coeruleus, the concentration of two different proteins was elevated in the hippocampus; a third protein was reduced in concentration in this brain area as a result of the lesion. Three proteins were affected in concentration in the cerebellum after the locus coeruleus lesion--two were elevated in concentration and one was reduced in concentration. No proteins were altered in concentration in the parietal cortex as a result of the lesion. Seventy days after neonatal treatment with 6-hydroxydopamine, a total of 6 proteins were found to be changed. Four of these (one in the hippocampus and 3 in the parietal cortex) were reduced in concentration while two proteins (both in the cerebellum) were elevated in concentration after neonatal treatment with the catecholamine neurotoxin. There was little overlap between those proteins affected in concentration by the bilateral lesion of the locus coeruleus and those changed by neonatal treatment with 6-hydroxydopamine. These results suggest that the concentration of a number of different proteins may, under normal physiological conditions, be regulated in vivo by norepinephrine in the brain.

Effect of 5,7-dihydroxytryptamine on the concentration of individual proteins in different areas of the rat brain.

Proteins which are apparently regulated in concentration in two different areas of the rat brain by the indole neurotransmitter serotonin were identified using two-dimensional gel electrophoresis combined with computerized scanning densitometry. Reduction in central serotonin levels produced a decrease in the concentration of 3 different proteins (2 in the parietal cortex, 1 in the hippocampus). Two proteins, both in the hippocampus, were elevated in concentration following serotonin depletion. These results demonstrate that there exist in the brain a limited number of proteins whose concentration is influenced by serotonin.

Subfornical organ: effects of salt loading and water deprivation on in vitro radioamino acid incorporation into individual proteins.

The subfornical organ of the brain has a role in the regulation of fluid balance in higher animals. In this study the effects of salt loading and water deprivation on specific proteins in this organ were investigated. For 4 days, 3 groups of rats were given an appropriate fluid diet (control, 2% NaCl and water deprived), with all groups having free access to food. Animals were killed by decapitation, and the subfornical organ was quickly dissected out and incubated for 6 h in a medium containing [35S]methionine and [35S]cysteine. Proteins from these organs were then separated by two-dimensional electrophoresis, and the resulting autofluorographs were analyzed by scanning densitometry. The results show that the incorporation of labeled amino acids into 8 proteins was changed due to the experimental manipulations.

Effect of reduction of cholinergic input on the concentration of specific proteins in different cortical regions of the rat brain.

The effect of lesioning the nucleus of the tractus diagonalis on the concentration of specific proteins in the hippocampus and the occipital cortex was assessed. Rats received either a sham or an electrolytic lesion and were killed 9 or 35 days later. Tissue samples were removed by microdissection and proteins were separated by two-dimensional gel electrophoresis. Gels were stained with silver, and then analyzed by quantitative computerized scanning densitometry. Of the 143 proteins analyzed, only four were found to be altered in concentration in both brain areas as a result of the lesion. Protein 82 (molecular weight 39,000, pI 6.5) was reduced 71% in the hippocampus and 50% in the occipital cortex 9 days after the lesion, while protein 109 (molecular weight 32,000, pI 6.4) was elevated 140% in the hippocampus and 130% in the occipital cortex at the same time point. Protein 6 (molecular weight 58,000, pI 5.7) was unchanged 9 days after the lesion but was elevated in concentration in both the hippocampus and the occipital cortex 35 days after lesioning. Protein 74 (molecular weight 39,000, pI 5.8) was elevated in concentration both 9 and 35 days after lesioning in the occipital cortex, but only at day 35 in the hippocampus. These results demonstrate that the concentration of these four proteins may be regulated by the cholinergic input to the hippocampus and the occipital cortex. The possibility exists that one or more of these proteins may be related to either the muscarinic or nicotinic cholinergic receptor in rat brain.

An apparent genetic polymorphism for a protein present in the hypothalamus of Sprague-Dawley rats.

Using two-dimensional gel electrophoresis, an apparent genetic polymorphism was detected in the hypothalamus of a group of inbred Sprague-Dawley rats. The proteins involved in this polymorphism have a molecular weight of 57,000 daltons and isoelectric points ranging from 6.1 to 6.3. These proteins met four criteria that should be met before a positional shift on two-dimension gels can be attributed to a genetic polymorphism. This is the first report of the existence of a genetic polymorphism in the brains of a group of inbred Sprague-Dawley rats. The functional significance of this polymorphism is currently under investigation.

Isolation of specific proteins affected by estradiol in the arcuate-median eminence of prepuberal female rats.

Prepuberal female rats (25 days of age) were injected with estradiol benzoate (EB 10 micrograms/rat, s.c. in oil) or oil vehicle. Forty-eight hours after treatment, all animals were decapitated, their brains removed and sectioned. The arcuate nucleus of the hypothalamus and median eminence were microdissected and processed for isoelectric focusing followed by slab gel electrophoresis. The resulting two-dimensional electrophoretic gels were analyzed to quantitate the specific proteins resolved using a scanning microdensitometric method. Out of 235 proteins measured, 8 proteins were found to be significantly increased and 4 were decreased by EB treatment. The proteins which increased in concentration ranged in molecular weight from 15 to 43 kDa and isoelectric points (pI) of 4.9 to 7.0. The 4 proteins decreased by the EB treatment were 44, 67, 74 and 80 kDa in molecular weight and their pI's ranged from 6.5 to 7.1. It is suggested that these proteins might be involved in some of the neuroendocrine effects that are induced by estradiol in this region of the brain.

Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.

Paroxetine is a selective serotonin re-uptake inhibitor (SSRI). In vitro studies show that it is able to produce a concentration-dependent competitive inhibition of serotonin uptake into brain synaptosomes. This effect can also be demonstrated following in vivo administration of the compound to animals. Paroxetine is almost completely absorbed following oral administration. However, the drug undergoes extensive first pass metabolism. As a result, less than 50% of a single dose of paroxetine reaches the general circulation. Paroxetine is primarily metabolised by the cytochrome P4502D6 isoenzyme. The compound has also been shown to inhibit the activity of this enzyme. As a result, plasma levels of compounds metabolised by the cytochrome P4502D6 isoenzyme can be increased in patients given paroxetine. Paroxetine has been extensively evaluated in clinical studies in depressed patients. The compound shows efficacy superior to placebo, and similar to that obtained with standard tricyclic or tetracyclic agents. Paroxetine also appears to be as efficacious as other SSRIs. The efficacy seen in short-term studies with paroxetine in the treatment of depression is maintained when the drug is given chronically. More recently, paroxetine has been shown to be efficacious in the treatment of panic disorder, obsessive-compulsive disorder, and social anxiety disorder. Nausea, headache and somnolence are the most common adverse events reported by patients given paroxetine. As with other selective serotonin re-uptake inhibitors, a significant percentage of men under therapy with paroxetine report abnormal ejaculation. Paroxetine is well-tolerated by elderly patients, and appears to be associated with few serious adverse events.

Summary from the 152nd meeting of the American Psychiatric Association.

The 152nd meeting of the American Psychiatric Association was held between 15th and 20th May 1999 in Washington DC; over 15,000 clinicians and researchers were expected to attend. The majority of the data presented at the meeting focused on new clinical research results for recently marketed products. Results from late stage clinical trials on new chemical entities in development were also presented at the conference.